Thursday, March 16, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

DARPA BAA for Pathogen Predators

by Global Biodefense Staff
July 21, 2014

The Defense Advanced Research Projects Agency (DARPA) is soliciting proposals for research supporting the potential use of bacterial “Pathogen Predators” as therapeutics against infections caused by Gram-negative antibiotic-resistant and priority threat pathogens.

The Pathogen Predators program will demonstrate that such infections might be effectively treated with live predatory bacteria. This approach would represent a significant departure from conventional antibacterial therapies that rely on small molecule antibiotics. While antibiotics have been remarkably effective in the past, their widespread use has led to the emergence of antibiotic-resistant bacterial infections that are difficult or impossible to treat.

The novel path explored in this program relies on the existence of predatory bacteria that prey upon and consume other Gram-negative bacteria. In vitro studies have shown that predators such as Bdellovibrio bacteriovorus and Micavibrio aeruginosavorus can prey upon more than one hundred different human pathogensand will also prey on multi-drug resistant bacteria. These findings present a unique opportunity for a predator-based therapeutic with activity against a wide range of Gram-negative pathogens, including those resistant to conventional small molecule antibiotics.

The Pathogen Predators program will answer three fundamental questions about bacterial predators:

  • Are predators toxic to recipient (host) organisms?
  • Against what pathogens (prey) are predators effective?
  • Can pathogens develop resistance to predation?

DARPA anticipates that the Pathogen Predators program will provide up to three years of funding for research and development.

Details for submitting proposals are available under Solicitation Number: DARPA-BAA-14-51. The response deadline is September 23, 2014.

Tags: AntimicrobialsBAADARPA

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC